Additional treatment for ER/PR-negatives?

Save as Favorite
Sign in to receive recommendations (Learn more)
Question from GMurray: Even though a young woman is not a candidate for either tamoxifen or Herceptin, is there any other protective drug she could go on following her treatments of mastectomy surgery, aggressive chemotherapy, and aggressive radiation?
Answers - Kathy D. Miller, M.D. At this point, no. If you've completed your surgery, chemotherapy, and radiation for a tumor that is ER/PR- and HER2-negative, you have completed all your therapy. There are several drugs in clinical trial that may be options in the future if those drugs are successful.
Jennifer Armstrong, M.D. For women who are in such a position and are interested in consideration of other strategies, I highly recommend you talk with your physician on consideration of protocols that may be investigating such agents. Among them are vaccine trials, and your doctor can help coordinate your learning more about what may be open to you. For most women, I think Dr. Miller's earlier points are very important in that it can be very helpful to understand how much you've already done, and to feel confident that you've availed yourself of every option we currently understand to be helpful.

The Ask-the-Expert Online Conference called Hormone-Receptor-Negative Breast Cancer featured Kathy D. Miller, M.D., Marisa Weiss, M.D., and moderator Jennifer Armstrong, M.D. answering your questions about a wide range of issues related to hormone-receptor-negative breast cancer.

Editor's Note: This conference took place in November 2005.

The materials presented in these conferences do not necessarily reflect the views of A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.

A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.

Was this article helpful? Yes / No

Springappeal17 miniad 1
Back to Top